WELCOME TO The PHARMACEUTICAL REPORT
Newsletter | Member Login | Signup
Home > Resources > Whitepapers > The convergence of the pharmaceutical and medicaldevices industries
May 26, 2022
I'm For Real
Enter your details once to access all our information and resources
PAION AG is a Specialty Pharma Company headquartered in Aachen, Germany with further sites in Cambridge, UK and New Jersey, US.
whitePaper | November 10, 2022
We know people don’t like to be sold to. And in the so-called ‘attention economy’, it is more important than ever that your business can utilise meaningful marketing and advertising practices to engage with your customers and secure their attention.
whitePaper | April 7, 2022
The United States defines a rare disease as a condition affecting fewer than 200,000 people in the country or one in which “there is no reasonable expectation” of recovering research and development costs.1 Examples of rare diseases include genetically-linked cancers, cystic fibrosis, and debilitating pediatric conditions like Gaucher disease and spinal muscular atrophy
whitePaper | July 8, 2022
Particulates are ubiquitous in parenteral drug products and remain a concern throughout their development and production1–3. These particles must be monitored to satisfy.
whitePaper | March 16, 2020
With the rapid onset of coronavirus in the United States, many pharma companies are being forced to prepare for a scenario in which their reps cannot visit providers and patients are limited in their ability to visit their healthcare professionals (HCP). The CDC has gone as far as recommending the use of telemedicine and patient portals as primary channels for HCPs and patients to interact.
whitePaper | April 20, 2023
Welcome to Pharmaprojects’ 2023 review of trends in pharmaceutical R&D. For over 30 years now, I’ve been taking an annual look at the evolution of pharma R&D, and in this article, I’llexamine the state of play at the start of 2023.
whitePaper | December 16, 2019
The use of FAIR (Findable, Accessible, Interoperable and Reusable) data in drug discovery and development could be transformational. But the pharma industry has been slow to embrace FAIR data — partially because of difficulties in establishing the necessary infrastructure and because of internal culture.
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE